Legato Capital Management LLC Reduces Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Legato Capital Management LLC reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.7% during the 4th quarter, Holdings Channel reports. The fund owned 8,803 shares of the biopharmaceutical company’s stock after selling 1,400 shares during the period. Regeneron Pharmaceuticals makes up about 0.6% of Legato Capital Management LLC’s holdings, making the stock its 20th largest holding. Legato Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $6,795,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock valued at $7,004,838,000 after acquiring an additional 26,884 shares during the last quarter. Dodge & Cox boosted its holdings in shares of Regeneron Pharmaceuticals by 18.9% in the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after acquiring an additional 724,562 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 6.0% in the 3rd quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company’s stock valued at $1,379,329,000 after acquiring an additional 139,647 shares during the last quarter. Capital World Investors boosted its holdings in shares of Regeneron Pharmaceuticals by 1.6% in the 3rd quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock valued at $1,123,609,000 after acquiring an additional 32,348 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 38.0% in the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after acquiring an additional 408,649 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported strong early results for Lynozyfic (linvoseltamab) in systemic AL amyloidosis, including rapid reductions in disease markers, a 100% complete response rate at the highest dose, and signs of improved heart and kidney function. The program remains investigational, but the data support a potential new growth opportunity. Article Title
• Positive Sentiment: Regeneron also announced that the European Medicines Agency accepted its filing for Otarmeni (lunsotogene parvec) in genetic hearing loss, a regulatory step that could expand the company’s rare-disease pipeline in the EU if approved. Article Title
• Neutral Sentiment: A Zacks piece highlighted REGN as a “strong value stock,” reflecting continued analyst support for the shares despite recent volatility. Article Title
• Negative Sentiment: Investor alerts and law-firm announcements said they are investigating possible securities claims against Regeneron after its Phase 3 melanoma trial for fianlimab plus Libtayo missed its primary endpoint versus Keytruda, raising legal and execution concerns. Article Title
• Negative Sentiment: Separate reports quoted Jim Cramer saying REGN could face more downgrades after the poor melanoma readout, reinforcing the market’s worry that the failed study may weigh on near-term sentiment. Article Title

Analysts Set New Price Targets

Several analysts have recently commented on REGN shares. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a report on Friday, May 1st. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $792.65.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $638.88 on Friday. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The company has a market cap of $67.54 billion, a price-to-earnings ratio of 15.57, a PEG ratio of 1.42 and a beta of 0.30. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The firm’s fifty day simple moving average is $731.45 and its two-hundred day simple moving average is $744.92.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s revenue was up 19.0% compared to the same quarter last year. During the same period last year, the firm posted $8.22 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the transaction, the director directly owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.